Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease

Health Technology Assessment

Type:

Extended Research Article Our publication formats
Authors:

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N
Journal:

Health Technology Assessment
Issue:

Volume: 5, Issue: 1
Published:

March 2001
Citation:

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease. Health Technol Assess 2001;5(1). https://doi.org/10.3310/hta5010
DOI:

https://doi.org/10.3310/hta5010